BioCurex, Inc.(fka BOCX)

[Kag]

Opportunity Knocking,
You posted: "Now what? Still in denial?"

My comment: An investor should be wondering how the data would have turned out in the real world of testing if the samples of blood to be tested had not been labeled as to what kind of cancer the cancer patients had? Obviously the cancer samples tested were already labeled because RECAF tests cannot differentiate between different types of cancer. What cutoff level of RECAF would have been used if the type of cancer was not previously known? There would have been no way to know in the real world. kag